China Pharma Holdings (CPHI) Capital Expenditures (2010 - 2025)
China Pharma Holdings (CPHI) posted Capital Expenditures of $454.0 for Q4 2025, down 25.7% on a QoQ basis from $611.0 in Q3 2025, and down 97.68% year-over-year from $19545.0 in Q4 2024.
China Pharma Holdings (CPHI) Capital Expenditures (2010 - 2025) Analysis & Trends
China Pharma Holdings' Capital Expenditures history runs 16 years deep, the most recent figure standing at $454.0 for Q4 2025.
- Quarterly Capital Expenditures fell 97.68% year-over-year to $454.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $59324.0 (down 27.92% YoY) and the FY2025 annual result came in at $59324.0, up 54.45% from the prior year.
- Capital Expenditures was $454.0 for Q4 2025 at China Pharma Holdings, down from $611.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $415977.0 in Q3 2021 and bottomed at -$55964.0 in Q1 2023.
- A 5-year average of $56635.2 and a median of $2959.0 in 2022 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2023 — Capital Expenditures tumbled 4123.29% — and 2024, when it soared 331.74%.
- China Pharma Holdings' Capital Expenditures stood at $7056.0 in 2021, then sank by 486.45% to -$27268.0 in 2022, then surged by 116.6% to $4527.0 in 2023, then soared by 331.74% to $19545.0 in 2024, then plunged by 97.68% to $454.0 in 2025.
- Business Quant data shows CPHI's Capital Expenditures at $454.0 in Q4 2025, $611.0 in Q3 2025, and -$65.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 168.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 110.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.95 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 99.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 39.90 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 51.00 Mn |
| 10 | China Pharma Holdings | 629,344.02 | 460,870.02 | 285,487.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 454.00 |
| Dec 31, 2025 | 454.00 |
| Sep 30, 2025 | 611.00 |
| Sep 30, 2025 | 611.00 |
| Jun 30, 2025 | -65.00 |
| Jun 30, 2025 | -65.00 |
| Mar 31, 2025 | 58,324.00 |
| Mar 31, 2025 | 58,324.00 |
| Dec 31, 2024 | 19,545.00 |
| Dec 31, 2024 | 19,545.00 |
| Sep 30, 2024 | -9,220.00 |
| Sep 30, 2024 | -9,220.00 |
| Dec 31, 2023 | 4,527.00 |
| Dec 31, 2023 | 4,527.00 |
| Sep 30, 2023 | 67,455.00 |
| Sep 30, 2023 | 67,455.00 |
| Jun 30, 2023 | -4,501.00 |
| Jun 30, 2023 | -4,501.00 |
| Mar 31, 2023 | -55,964.00 |
| Mar 31, 2023 | -55,964.00 |